Photo Courtesy of Neurona Therapeutics/Curtis Myers Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapy candidates for the treatment of neurological disorders, recently announced the successful completion of a $120 million financing. Neurona’s financial success is an encouraging sign for the stem cell and gene therapy sector, highlighting partnerships with investors and public organizations … Continue reading Neurona Therapeutics Raises $120M Financing, Cell Therapy Shows Positive Outcomes in CIRM-Funded Trial
Author: California Institute for Regenerative Medicine (CIRM)
CIRM invests $26 million in clinical-stage research, including Phase 2b trial for bipolar depression
Stock image of a dual tone brain by Getty Images South San Francisco, CA, Jan. 29, 2024 - The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded almost $26 million to fund various clinical research — from treating bipolar depression to advancing a therapy for spinal cord injury. … Continue reading CIRM invests $26 million in clinical-stage research, including Phase 2b trial for bipolar depression
CIRM Announces Interim CEO
Vito Imbasciani, PhD, MD, Board Chair and Jonathan Thomas, PhD, JD, Interim President and CEO South San Francisco, CA, Dec. 15, 2023 - The Independent Citizens Oversight Committee (ICOC), the governing board of the California Institute for Regenerative Medicine (CIRM), named Jonathan Thomas, PhD, JD as CIRM’s Interim President and CEO at the Dec. 14 meeting. … Continue reading CIRM Announces Interim CEO
Statement from CIRM on the FDA Approval of Gene Therapies for Sickle Cell Disease
The California Institute for Regenerative Medicine (CIRM) applauds and acknowledges the historic significance of the Food and Drug Administration (FDA) approval of Vertex and CRISPR Therapeutics’ CRISPR-based gene therapy (Casgevy) for sickle cell disease. As the first regulatory authorization of a CRISPR-based gene editing therapy in the world, this brings forth a new era of treatment options … Continue reading Statement from CIRM on the FDA Approval of Gene Therapies for Sickle Cell Disease
CIRM invests $17.5 million in clinical-stage research, including Phase 2 spina bifida trial
Diana Farmer, MD and Aijun Wang, PhD. Photo courtesy UC Davis Health South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, has awarded $17.5 million to fund clinical-stage research projects aimed at advancing stem cell and gene therapy treatments for a variety of conditions … Continue reading CIRM invests $17.5 million in clinical-stage research, including Phase 2 spina bifida trial
CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
John A. Zaia, MD, of Beckman Research Institute of City of Hope This year marks the 35th commemoration of World AIDS Day, a global event that aims to end human immunodeficiency virus (HIV) related stigma, honor people lost to the disease, and reaffirm the commitment to ensuring HIV is no longer a public health threat. … Continue reading CIRM Joins World AIDS Day Campaign, Commits $104 Million for HIV Research
Upcoming Funding Opportunity: ReMIND-L Awards
The California Institute for Regenerative Medicine (CIRM) is pleased to announce ReMIND-L, the first funding opportunity under CIRM’s ReMIND Program – a new discovery stage initiative supporting foundational research in the study of neuropsychiatric diseases. Applications are due March 5, 2024 by 2:00 p.m. PST. Applications will be available mid-December 2023 but no later than two months … Continue reading Upcoming Funding Opportunity: ReMIND-L Awards
CIRM invests more than $42 million in translational-stage research
South San Francisco, CA, Oct. 27, 2023– The California Institute for Regenerative Medicine (CIRM), the world’s largest institution dedicated to regenerative medicine, awarded $42.1 million to fund various translational research — from treating brain cancers and salivary gland conditions to advancing a therapy for a rare metabolic disease. The goal of CIRM’s Translational program is … Continue reading CIRM invests more than $42 million in translational-stage research
CIRM-Funded Program Targeting Rare Pediatric Disease Announces FDA Acceptance of Biologics License Application with Priority Review
South San Francisco, CA – The California Institute for Regenerative Medicine (CIRM), the world’s largest institute dedicated to regenerative medicine, would like to congratulate Rocket Pharmaceuticals, Inc, a leading late-stage biotechnology company, on receiving U.S. FDA acceptance of the Biologics License Application (BLA) and Priority Review for RP-L201 (marnetegragene autotemcel), a lentiviral vector (LV)-based gene … Continue reading CIRM-Funded Program Targeting Rare Pediatric Disease Announces FDA Acceptance of Biologics License Application with Priority Review
CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
The California Institute for Regenerative Medicine (CIRM) Alpha Clinics network specializes in delivering stem and gene cell clinical trials to patients. The key to the network’s success is the ability to foster partnerships with patients, medical providers, and clinical trial sponsors. The CIRM Alpha Clinics Network consists of nine leading medical centers throughout California. Every … Continue reading CIRM brings together experts in the 6th annual Alpha Clinics Network Symposium at UC Irvine
The Stem Cellar 